Invesco Ltd. Buys 166,526 Shares of Dr. Reddy's Laboratories Limited (NYSE:RDY)

Invesco Ltd. increased its position in Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 451.6% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 203,404 shares of the company's stock after purchasing an additional 166,526 shares during the period. Invesco Ltd.'s holdings in Dr. Reddy's Laboratories were worth $3,212,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in RDY. EverSource Wealth Advisors LLC grew its position in Dr. Reddy's Laboratories by 423.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,863 shares of the company's stock valued at $29,000 after purchasing an additional 1,507 shares in the last quarter. POM Investment Strategies LLC boosted its stake in shares of Dr. Reddy's Laboratories by 400.0% during the 4th quarter. POM Investment Strategies LLC now owns 2,275 shares of the company's stock valued at $36,000 after buying an additional 1,820 shares during the period. Farther Finance Advisors LLC grew its holdings in shares of Dr. Reddy's Laboratories by 461.0% during the 4th quarter. Farther Finance Advisors LLC now owns 2,547 shares of the company's stock valued at $40,000 after acquiring an additional 2,093 shares in the last quarter. Independence Bank of Kentucky increased its stake in shares of Dr. Reddy's Laboratories by 400.0% in the fourth quarter. Independence Bank of Kentucky now owns 2,775 shares of the company's stock worth $44,000 after acquiring an additional 2,220 shares during the last quarter. Finally, Allworth Financial LP raised its holdings in shares of Dr. Reddy's Laboratories by 447.8% during the fourth quarter. Allworth Financial LP now owns 2,728 shares of the company's stock worth $41,000 after acquiring an additional 2,230 shares in the last quarter. 3.85% of the stock is currently owned by hedge funds and other institutional investors.

Dr. Reddy's Laboratories Stock Down 0.4 %

RDY traded down $0.06 during trading on Thursday, reaching $13.87. 757,429 shares of the stock traded hands, compared to its average volume of 1,469,794. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.38. Dr. Reddy's Laboratories Limited has a fifty-two week low of $12.26 and a fifty-two week high of $16.89. The stock's 50-day simple moving average is $13.20 and its two-hundred day simple moving average is $14.19. The stock has a market cap of $11.57 billion, a price-to-earnings ratio of 22.08 and a beta of 0.51.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last announced its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.19 by $0.01. Dr. Reddy's Laboratories had a return on equity of 17.87% and a net margin of 17.25%. As a group, equities research analysts expect that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current year.

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.